REal World Data in LYmphoma and Survival in Adults (NCT03869619) — France Trial Details

Condition(s) studied

Diffuse Large B Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)T-cell Lymphoma (T-NHL)Hodgkin's Lymphoma (HL)Burkitt Lymphoma (BL))

Investigational drug(s) / intervention(s)

Real-life epidemiological platform of lymphoma in France

Real-life epidemiological platform of lymphoma in France: The REALYSA database will be described with the following characteristics: * Number of patients included per month in total and according to subtype of lymphoma * Number of patients in each region in total and according to subtype of lymphoma

Study summary

REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.

REALYSA is a platform perfectly set up to

* Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)…
* Document treatment effectiveness in real life and observance
* Address socio-economical questions

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

No

Inclusion Criteria: * Signature of the consent form for participation in the REALYSA cohort * Aged over 18 at the time of inclusion * Diagnosed with lymphoma in the last 6 months (180 days) * Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma Exclusion Criteria: * Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination) * Documented HIV infection * Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded: * Chronic lymphocytic leukemia/small lymphocytic lymphoma * Hairy cell leukemia and variant * Lymphoplasmacytic lymphoma * Waldenström macroglobulinemia * Primary DLBCL of the central nervous system (CNS) * T-cell large granular lymphocytic leukemia * Chronic lymphoproliferative disorder of NK cells * Mycosis fungoides * Sézary syndrome * Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists) * Post-transplant lymphoproliferative disorders (PTLD)

Primary outcome measure(s)

Progression-Free Survival (PFS) — 5 years

Trial sites (37)

Facility	City	Region	Status
Unité d'Hématologie Clinique, CH D'ARRAS	Arras	France	Recruiting
Service d'Hématologie, CHU Jean Minjoz	Besançon	France	Recruiting
Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine	Bordeaux	France	Recruiting
Institut Bergonié	Bordeaux	France	Recruiting
Centre Hospitalier Pierre Oudot	Bourgoin	France	Recruiting
Service d'Hématologie, Institut d'Hématologie de Basse Normandie	Caen	France	Recruiting
METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset,	Chambéry	France	Recruiting
Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Estaing, CHU de Clermont-Ferrand	Clermont-Ferrand	France	Recruiting
Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor	Créteil	France	Recruiting
CHU Francois MITTERRAND	Dijon	France	Recruiting
Service Hématologie, Centre Hospitalier de Dunkerque	Dunkirk	France	Recruiting
Service Oncologie médicale, Groupe Hospitalier Mutualiste de Grenoble, Institut Daniel Hollard,	Grenoble	France	Recruiting
CHD Vendée	La Roche-sur-Yon	France	Recruiting
Service d'Hématologie Clinique, Centre Hospitalier Universitaire Michallon	La Tronche	France	Recruiting
Clinique Victor Hugo	Le Mans	France	Recruiting
Centre hospitalier Libourne	Libourne	France	Recruiting
Service Oncologie médicale, HOPITAL SAINT VINCENT-DE-PAUL	Lille	France	Recruiting
Service des maladies du sang, Hôpital Claude Huriez, CHRU de Lille	Lille	France	Recruiting
Service Hématologie Clinique et Thérapie Cellulaire, CHU DE LIMOGES - HOPITAL DUPUYTREN,	Limoges	France	Recruiting
Département d'Hématologie et Oncologie, Centre Léon Bérard	Lyon	France	Recruiting
Département d'Hématologie Clinique, Hôpital Saint-Eloi,	Montpellier	France	Recruiting
Service Hématologie, GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER,	Mulhouse	France	Recruiting
Service d'Hématologie clinique, Centre Hospitalier Universitaire de Nantes	Nantes	France	Recruiting
Centre Hospitalier de Niort	Niort	France	Recruiting
Service Hématologie, Hôpital St Louis	Paris	France	Recruiting
CHU Haut-Lévêque	Pessac	France	Recruiting
Centre Hospitalier Lyon Sud	Pierre-Bénite	France	Recruiting
Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Poitiers	Poitiers	France	Recruiting
Hématologie Clinique, CHU PONTCHAILLOU	Rennes	France	Recruiting
Service Hématologie, Centre Hospitalier de Roubaix - Hôpital Victor Provo	Roubaix	France	Recruiting
Service Hématologie, UNIVERSITE DE ROUEN, CENTRE HENRI BECQUEREL	Rouen	France	Recruiting
Service Hématologie, CH YVES LE FOLL	Saint-Brieuc	France	Recruiting
Service Hématologie, Institut Curie - Hôpital René HUGUENIN	Saint-Cloud	France	Recruiting
Département d'Hématologie Clinique et Thérapie Cellulaire, Institut de Cancérologie Lucien Neuwirth	Saint-Priest-en-Jarez	France	Recruiting
Hôpitaux Universitaires de Strasbourg	Strasbourg	France	Recruiting
Institut Universitaire du Cancer	Toulouse	France	Recruiting
Hématologie Clinique, CH DE BRETAGNE ATLANTIQUE	Vannes	France	Recruiting

More Hospices Civils de Lyon trials in France

MEG Versus EEG HR for the Localization of the Epileptogenic Zone as Part of the Pre-surgical Assessment of Epilepsy Recruiting

Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) Starting soon

EARLY Intervention in Parent-professional Cooperation in Cerebral Palsy Recruiting

Evaluation of Penile Prosthesis Pump Manipulation Recruiting

Viscoelastic Tests (VET) Versus Conventional Coagulation Tests (CCT) for Management of Trauma-Induced Coagulopathy Starting soon

Other trials for the same condition

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma Active, not recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma Active, not recruiting